New Molecules as Drug Candidates for the Treatment of Upper and Lower GI Tract Ulcers

Author(s): Sandor Szabo, Ganna Tolstanova

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 21 , 2015

Become EABM
Become Reviewer
Call for Editor


Ulcers in the stomach, duodenum, ileum/jejunum and colon may look alike grossly and microscopically, but they have very different etiologies and pathogenesis. Unfortunately, there is virtually no etiologic treatment for any of these lesions which are also accompanied by limited or extensive inflammation. This article reviews four groups of new antiulcer drugs discovered and patented in our lab in Boston and Long Beach/Irvine (Table 1). Actually, the first group, pyrazole and its derivatives can be used for prevention, i.e., long lasting protection of gastric mucosa against alcohol- or NSAID-induced erosions. Dopamine seems to be a new etiologic treatment for both upper and lower GI tract ulcers. Angiogenic growth factors like bFGF or PDGF (daily administration as peptides orally or by rectal enemas, or as single or double-dose of gene therapy) accelerated the healing of gastroduodenal ulcers and UC, while VEGF seems to be effective only for upper GI tract ulcers. Last but not least, a novel group of angiogenic steroids which not only stimulate new blood vessel formation and granulation tissue production (essential elements of healing of ulcer types) but may also exert mild or prominent antiinflammatory action and seem to be ideal drugs for the treatment of IBD.

Keywords: Angiostatic steroids, angiogenic steroids, angiosteroids, angiogenic growth factors, bFGF, Crohn’s disease, dopamine, gastric and duodenal ulcers, inflammatory bowel diseases, PDGF, pyrazole derivatives, ulcerative colitis, VEGF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 09 June, 2015
Page: [2993 - 3001]
Pages: 9
DOI: 10.2174/1381612821666150514105026
Price: $65

Article Metrics

PDF: 22